[1] |
Zheng R, Qu C, Zhang S, et al. Liver cancer incidence and mortality in China: temporal trends and projections to 2030[J]. Chin J Cancer Res, 2018, 30(6):571-579.
|
[2] |
Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127):1301-1314.
|
[3] |
陈孝平,朱鹏. 以手术治疗为主的肝癌个体化综合治疗[J]. 中国实用外科杂志, 2016, 36(6):596-598, 602.
|
[4] |
樊嘉,王征. 原发性肝癌的手术切除[J]. 中华外科杂志, 2010, 48(3):167-168.
|
[5] |
Kwon OS, Choi SH, Kim JH. Inflammation and hepatic fibrosis, then hepatocellular carcinoma[J]. Korean J Gastroenterol, 2015, 66(6): 320-324.
|
[6] |
Zhou K, Gao CF, Zhao YP, et al. Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B[J].J Gastroenterol Hepatol, 2010, 25(9):1569-1577.
|
[7] |
Mallet V, Dhalluin-Venier V, Roussin C, et al. The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B[J]. Aliment Pharmacol Ther, 2009, 29(4):409-415.
|
[8] |
中华医学会感染病学分会,中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J/CD]. 中国肝脏病杂志(电子版), 2019, 11(4):5-27.
|
[9] |
O'Rourke JM, Sagar VM, Shah T, et al. Carcinogenesis on the background of liver fibrosis: implications for the management of hepatocellular cancer[J]. World J Gastroenterol, 2018, 24(39):4436-4447.
|
[10] |
Sasaki K, Shindoh J, Margonis GA, et al. Effect of background liver cirrhosis on outcomes of hepatectomy for hepatocellular carcinoma[J]. JAMA Surg, 2017, 152(3):e165059.
|
[11] |
梁宾勇,黄志勇,刘杨安, 等. 肝硬化对单个小肝细胞癌切除术后复发和患者长期生存的影响[J]. 中华外科杂志, 2012, 50(10): 865-869.
|
[12] |
Eminler AT, Irak K, Ayyildiz T, et al. The relation between liver histopathology and GGT levels in viral hepatitis: more important in hepatitis B[J]. Turk J Gastroenterol, 2014, 25(4):411-415.
|
[13] |
Sun P, Li Y, Chang L, et al. Prognostic and clinicopathological significance of gamma-glutamyltransferase in patients with hepatocellular carcinoma: a PRISMA-compliant meta-analysis[J]. Medicine, 2019, 98(19):e15603.
|
[14] |
Yang YT, Wang LL, Yan LT, et al. Platelet count is closely associated with the severity of liver injury in patients with chronic hepatitis B virus infection: a cross-sectional study[J]. Exp Ther Med, 2020, 20(1):243-250.
|
[15] |
Pang Q, Qu K, Zhang JY, et al. The prognostic value of platelet count in patients with hepatocellular carcinoma: a systematic review and meta-analysis[J]. Medicine, 2015, 94(37):e1431.
|
[16] |
Pang Q, Zhang JY, Xu XS, et al. Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence[J]. World J Gastroenterol, 2015, 21(18):5607-5621.
|
[17] |
Lisman T, Luyendyk JP. Platelets as modulators of liver diseases[J]. Semin Thromb Hemost, 2018, 44(2):114-125.
|
[18] |
Carr BI, Guerra V. Serum albumin levels in relation to tumor parameters in hepatocellular carcinoma patients[J]. Int J Biol Markers, 2017, 32(4):e391-396.
|
[19] |
Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians[J]. CMAJ, 2005, 172(3):367-379.
|
[20] |
Zhang LX, Lv Y, Xu AM, et al. The prognostic significance of serum gamma-glutamyltransferase levels and AST/ALT in primary hepatic carcinoma[J]. BMC Cancer, 2019, 19(1):841.
|
[21] |
Okamura Y, Ashida R, Yamamoto Y, et al. FIB-4 index is a predictor of background liver fibrosis and long-term outcomes after curative resection of hepatocellular carcinoma[J]. Ann Surg Oncol, 2016, 23(Suppl 4):467-474.
|
[22] |
Chen L, Cai BB, Zhou CJ, et al. A sample model established by S-index predicting overall survival after curative resection of primary hepatocellular carcinoma[J]. Cancer Manag Res, 2019(11):693-703.
|